Physician

Catherine Jennifer Bakewell, M.D.

According to 2025 Medicare claims, Catherine Bakewell, M.D. (NPI: 1336151786) practices rheumatology in the Salt Lake City-Murray, UT market, with the plurality of this provider's patient population coming from Salt Lake, UT. This provider's primary affiliated billing organization is IHC HEALTH SERVICES INC (NPI: 1629107305; TIN: 942854057) and primary practice location at 84102-2310. Bakewell is affiliated with the Castell Accountable Care, LLC (ACO ID: D0136), participating under the REACH model.

Bakewell's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 125 traditional Medicare patients, billed 38,752 HCPCS/CPT codes, and received $500,261 in Medicare payments. The top billing code was 99215 (Established patient office or other outpatient visit with high level of medical decision making, if using time, 40 minutes or more). Part D data shows 2,265 prescription claims across 237 beneficiaries totaling $861,343 in drug costs, led by Rinvoq (Upadacitinib). Open Payments data shows 115 records totaling $148,779. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has moved from a lower plateau to a higher plateau, from $199,988 to $500,261. Similarly, Part D prescription costs have moved sharply higher in recent years, from $169,279 to $861,343. For DME billing, this provider has fewer than 5 years of reported data, so a reliable trend cannot be assigned.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	122	17,856	$199,988
2016	113	21,510	$252,216
2017	98	22,785	$282,133
2018	101	28,816	$384,308
2019	94	35,898	$453,944
2020	96	42,579	$525,520
2021	99	33,828	$402,600
2022	114	37,110	$520,497
2023	111	32,810	$495,735
2024	125	38,752	$500,261

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	164	1,413	$169,279
2016	180	1,563	$267,590
2017	186	1,660	$320,480
2018	183	1,645	$290,776
2019	196	1,685	$344,287
2020	182	1,787	$451,488
2021	197	1,952	$627,110
2022	214	2,102	$814,436
2023	217	2,178	$753,057
2024	237	2,265	$861,343

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

No connected DME records

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99215	Established patient office or other outpatient visit with high level of medical decision making, if using time, 40 minutes or more	57	91	$124
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	82	142	$83
20611	Aspiration and/or injection of fluid large joint using ultrasound guidance	21	51	$60
96365	Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less	20	114	$43
G2211	Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's	21	21	$13

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Rinvoq	Upadacitinib	68	2,040	$459,966
Hydroxychloroquine Sulfate	Hydroxychloroquine Sulfate	301	25,210	$12,877
Methotrexate	Methotrexate Sodium	290	18,632	$6,159
Leflunomide	Leflunomide	94	6,768	$5,525
Celecoxib	Celecoxib	85	6,380	$3,413

Top 5 DME services in 2024

No connected or detailed DME service-level records for 2024.

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	114	$142,230	ABBVIE INC.
Research Payments	Reported research-related payment or transfer-of-value amount.	1	$6,549	Novartis Pharmaceuticals Corporation
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Catherine Jennifer Bakewell, M.D.?

Tedicare shows public-source Medicare data for Catherine Jennifer Bakewell, M.D. (NPI 1336151786), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Catherine Jennifer Bakewell, M.D. have ACO affiliation data?

Catherine Jennifer Bakewell, M.D. is shown with ACO affiliation data for Castell Accountable Care, LLC (REACH, ACO ID D0136).

What billing organization is linked to Catherine Jennifer Bakewell, M.D.?

Catherine Jennifer Bakewell, M.D. is linked to IHC HEALTH SERVICES INC (billing NPI 1629107305) in the available physician profile data.

Does Catherine Jennifer Bakewell, M.D. have Open Payments data?

Catherine Jennifer Bakewell, M.D. has 115 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.